Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients
| Autor: | Deborah L. Birx, Merlin L. Robb, Mark de Souza, Victoria R. Polonis, Thippawan Chuenchitra, Janice M. Darden, Somsak Chantakulkij, Arthur E. Brown, Sorachai Nitayaphan |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Immunology
Human immunodeficiency virus (HIV) HIV Infections Biology medicine.disease_cause Antibodies Viral Microbiology Giant Cells Neutralization Neutralization Tests Virology medicine Humans Primary isolate Neutralizing antibody Syncytium virus diseases Phenotype CD4 Lymphocyte Count Giant cell Insect Science biology.protein HIV-1 Pathogenesis and Immunity Antibody |
| Zdroj: | Journal of virology. 77(15) |
| ISSN: | 0022-538X |
| Popis: | A number of human immunodeficiency virus type 1 (HIV-1) non-B-subtype products have been developed for present or future vaccine trials; in Thailand, several studies using subtype B and/or CRF01_AE vaccines have been conducted. To better characterize the biologic properties of these subtypes, 70 HIV-1 subtype B and E isolates were phenotyped as syncytium-inducing (SI) or non-syncytium-inducing (NSI) isolates and assessed for sensitivity to neutralizing antibody (NAb). A significantly higher number of NSI subtype E viruses were neutralization sensitive than SI subtype E viruses ( P = 0.009), while no association between viral phenotype and sensitivity to NAb was observed for subtype B ( P = 0.856), suggesting a difference in the neutralization patterns of subtypes B and E. Strikingly, concurrent CD4 T-cell numbers were significantly lower for subtype E-infected patients whose isolates were more resistant to NAb, both for the overall study group ( P < 0.001) as well as for the 22 patients with NSI isolates ( P = 0.013). Characterization of the evolution of biologic properties of both B and non-B HIV-1 subtypes will provide a clearer understanding of the repertoire of antibodies that must be elicited for a vaccine to be effective against all phenotypes and subtypes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|